Results 81 to 90 of about 85,599,609 (253)

Homologous tumor‐targeting biomimetic nanozyme for synergistic NIR‐II photothermal and chemodynamic therapy

BMEMat, EarlyView.
Studies reveal that a biomimetic nanoplatform based on a cancer cell membrane‐camouflaged Au‐MnOx nanozyme (Au‐MnOx@CCM) can achieve synergistic antitumor therapy by combining NIR‐II mediated PTT with enhanced CDT, offering a promising strategy for precise and efficient tumor therapy. Abstract The therapeutic potential of nanozyme‐mediated chemodynamic
Xiaonan Li, Siman Luo, Yucheng Zuo, Liheng Chen, Houjuan Zhu, Jing‐Yi Zhu, Wei Xue   +6 more
wiley   +1 more source

The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from to

Therapeutic Advances in Chronic Disease, 2019
Dipeptidyl peptidase IV (DPP-4), an incretin glucagon-like peptide-1 (GLP-1) degrading enzyme, contains two forms and it can exert various physiological functions particular in controlling blood glucose through the action of GLP-1.
Shian-Ren Lin, Chia-Hsiang Chang, May-Jwan Tsai, Henrich Cheng, Jian-Chyi Chen, Max K. Leong, Ching-Feng Weng   +6 more
doaj   +1 more source

Model‐Informed Approaches for Pediatric Type 2 Diabetes Evidence Generation: Insights from a Model‐Based Longitudinal HbA1c Meta‐Analysis from EMA Marketing Authorization Applications

Clinical Pharmacology &Therapeutics, EarlyView.
Evidence generation for antihyperglycemic therapies in pediatric type 2 diabetes mellitus (T2DM) remains challenging, with most randomized trials failing to demonstrate statistically significant reductions in glycated hemoglobin (HbA1c), partly due to substantial between‐subject variability.
Pieter J. Colin, Efthymios Manolis, Jeroen V. Koomen   +2 more
wiley   +1 more source

Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison study

Diabetology & Metabolic Syndrome
Background To compare the effects of switching from dipeptidyl peptidase 4 (DPP-4) inhibitors to oral semaglutide on oxidative stress and glucose variability assessed by continuous glucose monitoring in patients with type 2 diabetes mellitus (T2DM ...
Makoto Ohara, Hiroki Yokoyama, Hiroaki Seino, Tomoki Fujikawa, Yo Kohata, Noriyuki Takahashi, Shunichiro Irie, Michishige Terasaki, Yusaku Mori, Tomoyasu Fukui, Sho-ichi Yamagishi   +10 more
doaj   +1 more source

The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction

Cardiovascular Diabetology, 2017
Background Previous studies regarding the cardioprotective effects of dipeptidyl peptidase 4 (DPP-4) inhibitors have not provided sufficient evidence of a relationship between DPP-4 inhibition and actual cardiovascular outcomes.
Mei-Tzu Wang, Sheng-Che Lin, Pei-Ling Tang, Wang-Ting Hung, Chin-Chang Cheng, Jin-Shiou Yang, Hong-Tai Chang, Chun-Peng Liu, Guang-Yuan Mar, Wei-Chun Huang   +9 more
doaj   +1 more source

DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes

, 2017
Plamen Kozlovski,1 Vaishali Bhosekar,2 James E Foley3 1Novartis Pharma AG, Basel, Switzerland; 2Novartis Healthcare Private Limited, Hyderabad, India; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA Introduction: Dipeptidyl peptidase-4 (DPP ...
Bhosekar V, Foley JE, Kozlovski P
core  

Treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metformin

Patient Preference and Adherence, 2016
Xiaomei Peng, Dingfeng Jiang, Dongju Liu, Oralee J Varnado, Jay P Bae Eli Lilly and Company, Global Patient Outcomes and Real World Evidence, Indianapolis, IN, USA Background: Metformin is an oral antidiabetic drug (OAD) widely used as first-line ...
Peng X, Jiang D, Liu D, Varnado OJ, Bae JP   +4 more
doaj  

Urogenital Infection Risk Associated With SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Target Trial Emulation

Clinical Pharmacology &Therapeutics, EarlyView.
Although sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are recommended for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), concerns regarding urogenital infections persist. Therefore, we evaluated the risk of urinary tract infection (UTI) and genital tract infection (GTI) after SGLT2i initiation in this population ...
Young‐Mi Ah, Junsung Nam, Jung Wook Youn, Yun Mi Yu, Soyoung Kang   +4 more
wiley   +1 more source

DPP-4 inhibitor restored level of p-ERK induced by 1 mM IS.

, 2014
Cells were exposed to 1 mM IS for 3 h and then treated with 100 ng/mL DPP-4 inhibitor. The treated cells were lysed for determination of p-ERK and ERK by immunoblot using specific antibodies and chemiluminescence development.
Chen-Hung Chang (586172), Mao-Feng Sun (586173), Wei-Jie Wang (186948), Sheng-Feng Hsu (586174), Ching-Sung Weng (586175)   +4 more
core   +1 more source

Fluorene‐based blue emitters: On the path to electrically pumped organic lasers

FlexMat, EarlyView.
Electrically pumped efficient operation remains unrealized, a major challenge in optoelectronics. Fluorene‐based blue‐emitting semiconductors are promising gain media, thanks to their structural tunability and favorable emission properties. This review summarizes recent advances, highlights their reliability and versatility in lasing, and outlines key ...
Yong Yan, Hao Li, Mengna Yu, Huiyin Wang, Jiangqiang He, Menghan Wu, Quanyou Feng, Linghai Xie   +7 more
wiley   +1 more source